Category: Eli Lilly
-
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies WASHINGTON — President Trump often brags that the “most-favored nation” deals he struck with drugmakers have set the country on a new path to no longer paying more than its fair share for prescription drug costs. But many details of the…
-
Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed…
-
STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data
STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy that would require all hospitals that participate in a federal drug discount program to submit comprehensive claims data, the first time…
-
STAT+: Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms
STAT+: Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese patients with an autoimmune condition that causes joint pain more than Taltz did alone. The data suggest the GLP-1 drug Zepbound,…
-
STAT+: With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market
STAT+: With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine from Eli Lilly, as the Danish drugmaker tries to seize market share among consumers paying cash for blockbuster GLP-1 therapies. Novo…
-
STAT+: Kennedy, a longtime pharma critic, embraces Trump deal to expand access to obesity drugs
STAT+: Kennedy, a longtime pharma critic, embraces Trump deal to expand access to obesity drugs WASHINGTON — Health Secretary Robert F. Kennedy Jr. was uncharacteristically chummy with pharma executives at the White House on Thursday as he cheered the Trump administration’s plan for lowering obesity medication prices. Kennedy has railed against drugmakers in the past, and…
-
STAT+: Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly
STAT+: Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly WASHINGTON — The Trump administration is nearing deals with Eli Lilly and Novo Nordisk to lower the prices of their weight loss drugs and expand access to them, people familiar with the talks told STAT. The companies have been close to…
-
STAT+: Eli Lilly, NVIDIA team up to build pharma’s biggest AI supercomputer
STAT+: Eli Lilly, NVIDIA team up to build pharma’s biggest AI supercomputer Eli Lilly announced a partnership with chipmaker NVIDIA on Tuesday to build what it claims will be the “most powerful supercomputer owned and operated by a pharmaceutical company.” Lilly’s technology investment is meant to help the drugmaker tap into the potential of artificial…
-
At a gathering of biopharma executives, a moment of wonder — and also of worry
At a gathering of biopharma executives, a moment of wonder — and also of worry Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit on Oct. 15-16, that kind of moment came when one of the top biopharmaceutical executives in the world met a toddler in a tuxedo. Read the…
-
Party in biotech land and AstraZeneca’s miscalculation
Party in biotech land and AstraZeneca’s miscalculation Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on Mizuho health care…
-
STAT+: Peter Marks, FDA vaccine regulator ousted by RFK Jr., joins Eli Lilly
STAT+: Peter Marks, FDA vaccine regulator ousted by RFK Jr., joins Eli Lilly WASHINGTON — Peter Marks, the former top vaccine regulator at the Food and Drug Administration, has joined Eli Lilly to oversee molecule discovery and infectious diseases — a move that quickly drew criticism for the revolving door between the agency and industry. Marks confirmed…
-
STAT+: Eli Lilly says it will raise drug prices in Europe to ‘make them lower’ in U.S.
STAT+: Eli Lilly says it will raise drug prices in Europe to ‘make them lower’ in U.S. Eli Lilly said Thursday that it would increase the prices of medicines in Europe and other developed markets “in order to make them lower” in the U.S., an apparent response to the Trump administration’s calls to do so.…
-
Closing a zombie biotech, and Lilly’s disappointing obesity readout
Closing a zombie biotech, and Lilly’s disappointing obesity readout How does a biotech company decide to shut itself down? Why does Eli Lilly have so much riding on its oral obesity candidate? And what’s the outlook for Vertex’s pain franchise? We discuss that and more on this on this week’s episode of “The Readout LOUD,”…
-
STAT+: Eli Lilly and AstraZeneca top a consultancy’s ranking of drug company R&D
STAT+: Eli Lilly and AstraZeneca top a consultancy’s ranking of drug company R&D A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap — but when it comes to invention, AstraZeneca, with its wealth of experimental cancer and rare disease therapies, ranks above its…
-
STAT+: Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list
STAT+: Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list A federal judge has sided with the U.S. Food and Drug Administration over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from…